Innovative GLP-1 Oral Medication Promises Significant Weight Loss
Eli Lilly's new oral GLP-1 medication, orforglipron, shows promise in significant weight loss and improved blood sugar control in clinical trials, offering a convenient alternative to injections for obesity treatment.
A groundbreaking development in weight management has emerged with Eli Lilly's new oral GLP-1 receptor agonist, orforglipron. In a recent late-stage clinical trial, participants with overweight, obesity, and type 2 diabetes experienced remarkable weight loss and improved blood sugar levels after using this once-daily pill.
Participants who received the highest dose of 36 milligrams lost an average of nearly 23 pounds (about 10.5% of their body weight) over a 72-week period. Additionally, the medication reduced their A1C levels—a key marker of blood sugar control—by approximately 1.8%. These results are promising, suggesting the pill's potential to effectively treat obesity and related metabolic conditions.
Compared to existing oral GLP-1 options such as Rybelsus, orforglipron offers the advantage of not requiring strict fasting or water restrictions, making it a more convenient option for many. Its development aims to provide an alternative to injectable treatments, which can be challenging for some patients.
The reported side effects were generally mild to moderate, with gastrointestinal discomfort, such as upset stomach, being the most common. If regulatory approval is granted, orforglipron could become an accessible and user-friendly treatment for millions struggling with obesity and type 2 diabetes.
Eli Lilly is also exploring additional uses for the medication, including potential benefits for high blood pressure and sleep apnea. With production already underway to meet anticipated demand, the company's chief scientific officer, Dr. Dan Skovronsky, highlighted the readiness to distribute the medication widely.
The trial findings, although not yet peer-reviewed, mark a significant step forward in oral obesity treatments and metabolic health management.
Source: https://medicalxpress.com/news/2025-08-glp-pill-people-pounds.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Weight Loss Before IVF Boosts Pregnancy Chances, Study Finds
Losing weight before IVF treatment can significantly improve the chances of pregnancy, especially unassisted conception, according to recent research. This review emphasizes the importance of preconception weight management in improving fertility outcomes for women with obesity.
Influenza A Infection Causes Changes in Microbiome and Brain Gene Expression
Influenza A virus infection in neonates can disrupt gut and nasal microbiomes and affect hippocampal gene expression, with maternal vaccination offering protective benefits. Learn how flu impacts brain health and microbiota.
Using a Popular Film to Map Brain Bias Towards Drug Cues in Heroin Users
Mount Sinai researchers use a popular film to map brain regions biased toward drug cues in heroin addicts, revealing potential pathways for treatment and recovery.
Understanding How the Body Responds to Extreme Conditions to Detect Early Signs of Illness
A groundbreaking study maps how the human body communicates under stress, offering new possibilities for early illness detection through real-time physiological monitoring.